Critical limb ischemia update and the evolving role of drug-elution technologies

ABSTRACT

Introduction: Critical limb ischemia (CLI) is a prevalent condition associated with cardiovascular mortality and limb loss.

Areas covered: This review discusses the epidemiology of CLI, revascularization options, and drug-elution therapies.

Expert commentary: Drug-eluting stents (DES) and drug-coated balloons (DCB) improve patency rates in the femoropopliteal segment, and are generally used as first-line therapies. For below-knee disease, angioplasty is the default strategy unless lesions are focal whereby DES can be used to reduce restenosis risk.

KEYWORDS:

• Peripheral artery disease
• critical limb ischemia
• paclitaxel
• drug coated balloon
• drug coated stent

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was not funded.